The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Safety and activity of CD5 CAR-T for R/R T-ALL and T-NHL
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, discusses the safety and anti-tumor activity of CD5-targeting CAR T-cells in relapsed/refractory (R/R) T-cell malignancies from a phase 1 study (NCT03081910). The results indicated that CD5 CAR T-cells are safe and can induce clinical responses in heavily treated patients with R/R CD5+ T-ALL and T-NHL without inducing complete T-cell aplasia. Importantly, elimination of malignant T-cells may allow previously ineligible patients to proceed to transplant. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
